Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our new X-Twist suture anchor system in sports medicine is gaining early traction in the market following our Q1 full market release of the peak version with ongoing very positive surgeon feedback |
| So we saw a strong Q2, and Mitek did for Monovisc, principally, and outside the U.S., we saw it for Cingal, and that's been a continuing trend |
| I'm very pleased to say that Anika delivered strong second quarter results with 12% overall revenue growth driven by our OA Pain Management business with strong gross margins and improved bottom line performance |
| Looking at the core parts of the business, which excludes non-orthopedics, we grew 16%, which is an outstanding result as our products continue to gain traction in the markets we serve |
| Our OA Pain Management business was stronger than anticipated with 22% revenue growth led by accelerating Monovisc growth globally, strong Cingal growth outside the U.S |
| Integrity is an exciting product |
| We continue to get very strong clinical feedback on them with X-Twist and RevoMotion |
| Our OA Pain Management products have the best clinical performance of any on the market |
| We're pleased to see J&J's robust results as they continue to further expand our number one market share position in the U.S |
| OA Pain Management market and the strong performance of our international team with Cingal, together with Monovisc and Orthovisc, posting double-digit growth in the quarter |
| On our Joint Preservation business, first of all, we've built out a number of really strong products |
| Together, we are building real momentum as we work to achieve our mission of restoring active living for people around the world |
| And we've been able to self-fund this portfolio development and continue to maintain a healthy balance sheet with a solid cash position and no debt |
| We're pleased to see the acceleration in growth of our already market-leading visco supplement for OA Pain Management, the tremendous opportunities afforded by our next-generation non-opioid OA Pain Management product, Cingal, the growing strength of our HA-based regenerative portfolio, including meaningful differentiated regenerative solutions for cartilage and rotator cuff repair and the progress we've made in further strengthening our already robust portfolio across sports medicine and minimally-invasive joint solutions |
| Our Joint Preservation and Restoration portfolio continues to strengthen, and our newest products drove continued growth in the second quarter, though slower than we originally expected as some of our distributors experienced the recent industry dynamic of pent-up demand, causing a greater focus on large joints |
| Before we open the call up for Q&A, I want to reiterate our excitement as the progress we've made in building on Anika's historic strength in hyaluronic acid addressing OA Pain to now assembling best-in-class solutions across early intervention orthopedics |
| We still see a tremendous opportunity for growth in the JPR business, especially with our new product launches, and we're still very bullish on the business |
| I'm pleased to report that our newest Joint Preservation product, the RevoMotion, Reverse Shoulder Arthroplasty System, which has been in limited release since earlier this year is seeing growing momentum as we continue to receive very positive clinical feedback |
| As the clinical evidence for augmentation in rotator cuff repairs continues to build, we expect the momentum and adoption to increase as well, which is a clear win for both surgeons and their patients |
| We have no changes to the rest of our P&L outlook and continue to expect adjusted gross margin for the year to be roughly in line with last year and adjusted EBITDA margin to be positive for the year in the low single digits as compared to 8% last year, reflecting the cost to demonstrate compliance with expanded global regulations, primarily for our legacy OA Pain Management products, enhanced operational capabilities to support sustainable growth as well as the development and launch of key joint preservation products |
| This outlook is up compared to our previous range of $93.5 million to $96 million on a strong progress year-to-date and positive momentum in the market |
| Lastly, we're very pleased with our progress in developing our HA-based regenerative rotator cuff patch system, which we have named Integrity |
| So yes, I was very pleased with the quarter |
| That's up 4% to 6% over last year, as our market-leading products continue to gain adoption globally |
| As Anika maintains a healthy balance sheet and is well positioned to continue to self-fund our growth initiatives to drive shareholder value |
| Integrity is a key value driver for Anika, allowing us to serve the fast-growing regenerative rotator cuff repair market with an innovative solution tailored for ease of use by surgeons |
| But the underlying end-user sales continue the strong momentum, and that's the basis for the raise and for the strength in that business |
| Our adjusted gross margin, which excludes the acquisition-related amortization, increased to 69% in the quarter, up from 67% last year due to business growth, favorable product mix and manufacturing efficiencies |
| And both of which were very encouraging, and that's why we were able to raise our guidance |
| Revenue in our largest product family, OA Pain Management, increased 22% to $29.3 million due to sales growth on increasing global customer demand led by Monovisc and Cingal, and favorable ordering patterns from both J&J Mitek in the U.S |
| Statement |
|---|
| Our previous range was $55.5 million to $58 million, and our revised growth outlook reflects a slower-than-expected sales ramp this year through our hybrid channel, as Cheryl mentioned |
| Our non-orthopedic revenue declined 33% to $2.3 million, primarily reflecting unfavorable year-over-year order timing by our veterinary distributor as well as the continued impact from our exit from legacy product lines that do not support our growth and profitability objectives, which saw higher revenues last year from last time buys |
| The lower non-orthopedic revenues reduced total company growth in the quarter by approximately 4 percentage points |
| We now expect non-orthopedic revenue of $9.5 million to $10 million, a decrease of approximately 30% from last year, primarily due to last year's last time buys of legacy products and veterinary order timing |
| The lower non-orthopedic revenues reduced total company growth this year by approximately 4 percentage points |
| And so, I think from a focus perspective, there was definitely from an Anika -- in Anika view, there was probably a distraction there for those distributors being very focused on the Hip and Knee side of the business |
| On the other side of the business, the Joint Preservation down $1 million in the first quarter, which I don't think you expected |
| That's down from our net loss of $2.8 million or $0.20 per share in the second quarter of last year |
| Our net loss for the quarter was $2.7 million or $0.19 per share |
| And we called that out in the first quarter, we said it was probably going to be a headwind in the second quarter, and that's exactly what we saw |
| Based on your guidance, you're looking for that to come down to average around $23.5 million, $24 million a quarter from the back half of the year |
| So yes, the second half, the transfer units will be lower than in the first half, and that's what was reflected in the guide |
| I'm just curious what some of the drivers there were? And why that outlook is a little bit lighter than where it was exiting last quarter? Cheryl Blanchard Yes |
| As you know, and you've been following Anika for quite some time, you got a lumpy revenue stream uneven ordering patterns that just happens, largely when you're dealing with a large company like J&J that can happen from quarter-to-quarter |
| I apologize if I missed this detail earlier |
| Please also see our most recent SEC filings for more information about risk factors that could affect our performance |
Please consider a small donation if you think this website provides you with relevant information